Stem cell companies using new US laws to provide unapproved products to seriously ill patients

A new US law, designed to give terminally ill patients access to unproven drugs, is being invoked by stem cell companies to make unapproved stem cell products available, in a move that has an Australian expert concerned.

Professor John Rasko is one of a group of experts who are warning that the US Right to Try Act is being used by stem cell companies to provide unapproved products to seriously ill patients.

They say the use of this law by businesses selling unapproved stem cell products raises unsettling questions about their commitment to evidence based care.

Source: Read Full Article

Related posts:
  1. Scientists bring new hope to brain tumor patients
  2. Study provides new insight into use of cell replacement therapies to treat muscular dystrophies
  3. How organs form helps stem cell researchers in their quest to develop future treatments of diabetes and cancer
  4. Computer kidney could provide safer tests for new medications
  5. Scientists identify promising new target to combat Alzheimer’s disease